Modality
Radioligand
MOA
PLK4i
Target
CD20
Pathway
Hedgehog
Parkinson'sPancreatic Ca
Development Pipeline
Preclinical
~May 2017
→ ~Aug 2018
Phase 1
Nov 2018
→ May 2026
Phase 1Current
NCT08108068
1,965 pts·Pancreatic Ca
2018-11→2026-05·Completed
NCT07750865
441 pts·Pancreatic Ca
2023-06→TBD·Recruiting
2,406 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-05-162mo awayInterim· Pancreatic Ca
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1
Complet…
P1
Recruit…
Catalysts
Interim
2026-05-16 · 2mo away
Pancreatic Ca
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08108068 | Phase 1 | Pancreatic Ca | Completed | 1965 | ORR |
| NCT07750865 | Phase 1 | Pancreatic Ca | Recruiting | 441 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| CRS-6525 | CRISPR Therapeutics | Phase 2 | CD20 | |
| AKR-4818 | Akero | Approved | CD20 | |
| Peminaritide | iTeos | NDA/BLA | CD20 | |
| Liravorutinib | Biomea Fusion | Phase 1/2 | GPRC5D |